Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years
NCT04341389 is registered in ClinicalTrials.gov with Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years
- Lead sponsor
- Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 12, 2020
- Completion date
- December 31, 2020
- Enrollment
- 508 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.